Definition, Classification, and Epidemiology of Pulmonary Arterial Hypertension

ABSTRACT

Pulmonary arterial hypertension (PAH) is a distinct subgroup of pulmonary hypertension that comprises idiopathic PAH, familial/heritable forms, and PAH associated with connective tissue disease, congenital heart disease, portal hypertension, human immunodeficiency virus (HIV) infection, and some other conditions. The hemodynamic definition of PAH was recently revised: PAH is now defined by a mean pulmonary artery pressure at rest ≥25 mm Hg in the presence of a pulmonary capillary wedge pressure ≤15 mm Hg. The exercise criterion (mean pulmonary artery pressure ≥30 mm Hg during exercise) that was used in the old definition of PAH has been removed because there are no robust data that would allow defining an upper limit of normal for the pulmonary pressure during exercise. The revised classification of pulmonary hypertension still consists of five major groups: (1) PAH, (2) pulmonary hypertension due to left heart disease, (3) pulmonary hypertension due to chronic lung disease and/or hypoxia, (4) chronic thromboembolic pulmonary hypertension, and (5) miscellaneous forms. Modifications have been made in some of these groups, such as the addition of schistosomiasis-related pulmonary hypertension and pulmonary hypertension in patients with chronic hemolytic anemia to group 1.

KEYWORDS

Pulmonary hypertension - pulmonary arterial hypertension - epidemiology - classification

REFERENCES

• 1 Galiè N, Torbicki A, Barst R The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension.  Eur Heart J. 2004;  25 2243-2278
• 2 Behr J, Ryu J H. Pulmonary hypertension in interstitial lung disease.  Eur Respir J. 2008;  31 1357-1367
• 3 Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD.  Eur Respir J. 2008;  32 1371-1385
• 4 Ghio S, Gavazzi A, Campana C et al.. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure.  J Am Coll Cardiol. 2001;  37 183-188
• 5 Abramson S V, Burke J F, Kelly Jr J J et al.. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy.  Ann Intern Med. 1992;  116 888-895
• 6 Oswald-Mammosser M, Weitzenblum E, Quoix E et al.. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure.  Chest. 1995;  107 1193-1198
• 7 Hamada K, Nagai S, Tanaka S et al.. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis.  Chest. 2007;  131 650-656
• 8 Rich S, Dantzker D R, Ayres S M et al.. Primary pulmonary hypertension: a national prospective study.  Ann Intern Med. 1987;  107 216-223
• 9 Humbert M, Sitbon O, Chaouat A et al.. Pulmonary arterial hypertension in France: results from a national registry.  Am J Respir Crit Care Med. 2006;  173 1023-1030
• 10 Peacock A J, Murphy N F, McMurray J J, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension.  Eur Respir J. 2007;  30 104-109
• 11 Fisher M R, Criner G J, Fishman A P NETT Research Group et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema.  Eur Respir J. 2007;  30 914-921
• 12 Arcasoy S M, Christie J D, Ferrari V A et al.. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.  Am J Respir Crit Care Med. 2003;  167 735-740
• 13 Paulus W J, Tschöpe C, Sanderson J E et al.. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.  Eur Heart J. 2007;  28 2539-2550
• 14 Simonneau G, Galiè N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 5S-12S
• 15 Dupuis J, Hoeper M M. Endothelin receptor antagonists in pulmonary arterial hypertension.  Eur Respir J. 2008;  31 407-415
• 16 Wilkins M R, Wharton J, Grimminger F, Ghofrani H A. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.  Eur Respir J. 2008;  32 198-209
• 17 Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension.  Eur Respir J. 2008;  31 891-901
• 18 Galiè N, Seeger W, Naeije R, Simonneau G, Rubin L J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 81S-88S
• 19 Sitbon O, Gressin V, Speich R et al.. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  170 1212-1217
• 20 Hoeper M M, Seyfarth H J, Hoeffken G et al.. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.  Eur Respir J. 2007;  30 1096-1102
• 21 Deng Z, Morse J H, Slager S L et al.. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.  Am J Hum Genet. 2000;  67 737-744
• 22 Trembath R C, Thomson J R, Machado R D et al.. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.  N Engl J Med. 2001;  345 325-334
• 23 Machado R F, Gladwin M T. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension.  Br J Haematol. 2005;  129 449-464
• 24 Morris C R, Kato G J, Poljakovic M et al.. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.  JAMA. 2005;  294 81-90
• 25 Jaïs X, Ioos V, Jardim C et al.. Splenectomy and chronic thromboembolic pulmonary hypertension.  Thorax. 2005;  60 1031-1034
• 26 de Cleva R, Herman P, Pugliese V et al.. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis—prospective study.  Hepatogastroenterology. 2003;  50 2028-2030
• 27 Thenappan T, Shah S J, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006.  Eur Respir J. 2007;  30 1103-1110
• 28 Humbert M. The burden of pulmonary hypertension.  Eur Respir J. 2007;  30 1-2
• 29 Abenhaim L, Moride Y, Brenot F International Primary Pulmonary Hypertension Study Group et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension.  N Engl J Med. 1996;  335 609-616
• 30 Boutet K, Frachon I, Jobic Y et al.. Fenfluramine-like cardiovascular side-effects of benfluorex.  Eur Respir J. 2009;  33 684-688
• 31 Souza R, Humbert M, Sztrymf B et al.. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases.  Eur Respir J. 2008;  31 343-348
• 32 Chin K M, Channick R N, Rubin L J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?.  Chest. 2006;  130 1657-1663
• 33 Wigley F M, Lima J A, Mayes M, McLain D, Chapin J L, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).  Arthritis Rheum. 2005;  52 2125-2132
• 34 Denton C P, Black C M. Pulmonary hypertension in systemic sclerosis.  Rheum Dis Clin North Am. 2003;  29 335-349 , vii
• 35 Mukerjee D, St George D, Coleiro B et al.. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.  Ann Rheum Dis. 2003;  62 1088-1093
• 36 Hoeper M M. Pulmonary hypertension in collagen vascular disease.  Eur Respir J. 2002;  19 571-576
• 37 Condliffe R, Kiely D G, Peacock A J et al.. Connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era.  Am J Respir Crit Care Med. 2008;  179 151-157
• 38 Duffels M G, Engelfriet P M, Berger R M et al.. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry.  Int J Cardiol. 2007;  120 198-204
• 39 Hoeper M M, Krowka M J, Strassburg C P. Portopulmonary hypertension and hepatopulmonary syndrome.  Lancet. 2004;  363 1461-1468
• 40 Sitbon O, Lascoux-Combe C, Delfraissy J F et al.. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.  Am J Respir Crit Care Med. 2008;  177 108-113
• 41 Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension.  Eur Respir J. 2003;  22 358-363
• 42 Montani D, Price L C, Dorfmuller P et al.. Pulmonary veno-occlusive disease.  Eur Respir J. 2009;  33 189-200
• 43 Dorfmüller P, Humbert M, Perros F et al.. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases.  Hum Pathol. 2007;  38 893-902